Real-world effectiveness with the recommended single dose of respiratory syncytial virus (RSV) vaccination dipped in older ...

Veterans aged 60 years and older who received a single dose of the respiratory syncytial virus (RSV) prefusion F3 (RSVPreF3) or RSV prefusion F (RSVpreF) vaccine remained protecte ...

Vaccine uptake may not be much better during the 2024–25 respiratory virus season. Fewer than two in five (38%) eligible recipients plan to get an RSV vaccine, according to a survey conducted in ...

The effectiveness of a single respiratory syncytial virus (RSV) vaccine dose declined among older adults, potentially suggesting the need for booster shots among this demographic. That is according to ...

A robust antibody response was found in patients in residents of long-term care facilities who were given the respiratory syncytial virus (RSV) vaccine. RSV is a major respiratory infection that ...

The RSV vaccine is specifically created and approved for administration in older adults. Back in March, the FDA recommended ...

Lo que las personas mayores deben saber esta temporada de RSV (StatePoint) Each year, up to 160,000 older adults living in the United States are hospitalized and as many as 10,000 die due to ...

RSV hospitalization rates in older adults reached 58.3 per 100,000 in winter 2023-24, nearly half the rate of influenza at 114.6 per 100,000. Mortality and clinical outcomes were comparable between ...

Oct. 3, 2024 -- Respiratory Syncytial Virus (RSV) is often thought of as a childhood illness, but it poses a significant threat to older adults as well. According to the CDC, RSV infected ...

Vaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research. The ...

The researchers found that RSV vaccination was 82.3% effective in protecting against hospital admission for participants with any RSV-associated ARI, 86.7% effective against hospital admissions for ...